#mcspc

OncLive

@onclive.bsky.social

3 weeks ago

Dr Bilen on Real-World OS Benefit With Apalutamide vs Darolutamide in mCSPC | OncLive Mehmet Bilen, MD, discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.

WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here 📽️: www.onclive.com/view/dr-bile...
#oncology #pcsm #mcspc

OncLive

@onclive.bsky.social

3 weeks ago

Dr Bilen on a Real-World Analysis of Apalutamide vs Darolutamide in mCSPC | OncLive Mehmet Bilen, MD, discusses the rationale for a real-world analysis of apalutamide vs darolutamide in mCSPC.

WATCH 👀: Mehmet Bilen, MD, of @winshipcancer.emory.edu discusses a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here ➡️: www.onclive.com/view/dr-bile...
#oncology #medtwitter #prostatecancer #pcsm #mcspc

Therapeutic Advances in Medical Oncology

@tamedoncol.bsky.social

1 month ago

How deep should PSA go in mCSPC?
⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design?
🔗 buff.ly/zGZ7FfA
#ProstateCancer #Oncology #mCSPC #PSA #CancerResearch

Journal of Health Economics and Outcomes Research

@journalheor.bsky.social

2 months ago

In a study using real-world data, Black patients with #mCSPC treated with #apalutamide achieved earlier and higher deep PSA responses than those receiving #abiraterone acetate, suggesting improved outcomes in an understudied population. jheor.org/article/151273 #HEOR #prostatecancer

OncoDaily

@oncodaily.bsky.social

2 months ago

FDA Approves Niraparib Plus Abiraterone for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer - OncoDaily FDA approves niraparib plus abiraterone and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on AMPLITUDE trial data.

FDA Approves Niraparib Plus Abiraterone for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer

@fda.gov

oncodaily.com/fda-approval...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Niraparib #Abiraterone #BRCA2 #ProstateCancer #MCSPC

Medthority

@medthority.bsky.social

8 months ago

Could earlier genomic testing be the key to better prostate cancer treatment? Gerhardt Attard presents the updates from #ASCO25 you need to know, including a new approach in #mCSPC that can significantly reduce disease progression #MedSky #Oncology

ow.ly/ni2050WaQwG

Ravi Madan

@ravimadan.bsky.social

9 months ago

Most expected #Arches 5 yr follow up data to be pro-forma #ASCO25
@ascocancer.bsky.social

But then this data popped up 👀
Less clear benefit of Enza+ADT in low volume #mCSPC

Should this raise ?s for #mCSPC intensification w/#parp & #LU-psma

Implications for over treating PSMA+ recurrence?

American Society of Clinical Oncology

@ascocancer.bsky.social

9 months ago

NEW from #ASCO25: AMPLITUDE research summary: Adding niraparib to standard treatment can help slow cancer growth for people with #mCSPC with HRR gene alterations ➡️ www.asco.org/practice-pat...

#PCSM #ProstateCancer

Ravi Madan

@ravimadan.bsky.social

1 year ago

“Truqap combination (w/abiraterone) in #PTEN -deficient #mCSPC #ProstateCancer demonstrated statistically significant & clinically meaningful improvement in rPFS in #CAPItello-281 Phase III trial”

Look forward to seeing this data & relative toxicity

Sasanka

@sasankaatapattu.bsky.social

1 year ago

a blue sky with white clouds floating in it . ALT: a blue sky with white clouds floating in it .

💳 | 📱| 🔑
On the road to Columbus. Excited to dive into the latest data & treatment options for #mCSPC and #NMIBC patients today #Oncology #UroOnc
#prostatecancer #bladdercancer